<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82466">
  <stage>Registered</stage>
  <submitdate>7/12/2007</submitdate>
  <approvaldate>12/12/2007</approvaldate>
  <actrnumber>ACTRN12607000631404</actrnumber>
  <trial_identification>
    <studytitle>A double-blind randomised controlled trial of oxytocin bolus plus placebo infusion versus oxytocin bolus plus oxytocin infusion at elective caesarean section.</studytitle>
    <scientifictitle>A double-blind randomised controlled trial of oxytocin bolus plus placebo infusion versus oxytocin bolus plus oxytocin infusion for the prevention of uterine atony and post partum haemorrhage at elective caesarean section.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Postpartum haemorrhage</healthcondition>
    <healthcondition>Elective caesarean section</healthcondition>
    <healthcondition>Uterine atony</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>For the management of the third stage of labour at elective caesarean section, a single dose intravenous bolus injection of 5 IU (international units) oxytocin plus 20 IU (international units) oxytocin intravenous infusion (rate 250mls hour infused over 4 hours).</interventions>
    <comparator>For the management of the third stage of labour at elective caesarean section, a single dose intravenous bolus injection of  5 IU (international units) oxytocin alone.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Requirement for additional uterotonic measures</outcome>
      <timepoint>24 hours postpartum</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of fluid (crystalloid/colloid) replacement required to correct hypovolaemia.</outcome>
      <timepoint>Prior to discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of women administered blood products (packed red cells, platelets, fresh frozen plasma).</outcome>
      <timepoint>Prior to discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A return to theatre within 24 hours in order to arrest bleeding/haemorrhage.</outcome>
      <timepoint>24 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>A change in postnatal day 1 haemoglobin ("Hb") (compared to preoperative measurement).</outcome>
      <timepoint>24 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite serious maternal morbidity/mortality (Admission to High Dependency Unit/Intensive Care Unit "HDU/ITU", Prolonged postnatal stay (&gt; 5 days), hysterectomy, haematologic dysfunction (e.g disseminated intravascular coagulation, laparotomy, blood loss &gt;1,000mls, death</outcome>
      <timepoint>Prior to discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Pregnancy: Singleton only Fetus: Alive only Gestation: 37 weeks - 41 weeks Surgery: Elective lower segment caesarean section Anaesthesia: Regional anaesthesia (spinal, epidural, combined spinal epidural (CSE)) Past medical history: No significant maternal medical or obstetric disorders Parity: &lt;3 (equal to or less than 3): Pre-op Haemoglobin: "Hb" &gt; (equal to or more than) 100g/dl Language: Fluency in English Age: &gt;18 years of age (equal to or more than)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Active labour (presence of regular uterine activity accompanied by cervical dilation)

Emergency caesarean section

General anaesthesia

(Less than) &lt;37 completed weeks of pregnancy

Fetal demise 

Multiple pregnancy

Polyhydramnios

Macrosomic fetus (Estimated fetal weight "EFW" &gt;4.5 kg)

Past history of post partum haemorrhage 'PPH' requiring additional measures

Antepartum haemorrhage (requiring hospitalisation)

Known abnormality of placentation (e.g. placenta praevia, vasa, praevia, accreta)
Presence of uterine leiomyoma
 
Classical uterine incision (Past history of or intention at this lower segment caesarean section "LUSCS").

Evidence of intrauterine infection e.g. chorioamnionitis

Significant maternal medical disorders: Cardiac disease/arrhythmias. Hypertensive disorders: chronic/essential hypertension /pregnancy induced hypertension "PIH"/Pre eclampsia  +/- magnesium sulphate "MgSO4" therapy. Known inherited coagulopathies, haemorrhagic/bleeding disorders (family history/known carriers of same) or other abnormalities of coagulation. Currently prescribed anticoagulant medication. Obstetric cholestasis. Connective tissue disorders

Past history of ruptured uterus 

Previous adverse reaction to oxytocin (SyntocinonÂ®)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Stratified allocation - stratified for parity and hospital</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/03/2008</anticipatedstartdate>
    <actualstartdate>1/03/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>2/04/2014</actualenddate>
    <samplesize>948</samplesize>
    <actualsamplesize>474</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3168</postcode>
    <postcode>3175</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress>Department of Obstetrics
Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Monash University</fundingname>
      <fundingaddress>Department of Obstetrics
Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This double-blind randomised controlled trial, will assess the relative effectiveness of two different oxytocin regimens for the prevention/treatment of haemorrhage after a caesarean section</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health Human Research and Ethics Committee</ethicname>
      <ethicaddress>Research Directorate
Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</ethicaddress>
      <ethicapprovaldate>16/01/2008</ethicapprovaldate>
      <hrec>*07212C</hrec>
      <ethicsubmitdate>5/12/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Euan M. Wallace</name>
      <address>Department of Obstetrics
Monash University
Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+61 3 95945145</phone>
      <fax>+61 3 95946389</fax>
      <email>euan.wallace@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Ms. Joanne C. Mockler</name>
      <address>Department of Obstetrics
Monash University
Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+61 3 85722840</phone>
      <fax>+61 3 95946389</fax>
      <email>joanne.mockler@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms. Joanne C. Mockler</name>
      <address>Department of Obstetrics
Monash University
Monash Medical Centre
246 Clayton Road
Clayton VIC 3168</address>
      <phone>+61 3 85722840</phone>
      <fax>+61 3 95946389</fax>
      <email>joanne.mockler@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Euan M.Wallace</name>
      <address>Department of Obstetrics and Gynaecology
Monash University
L5 Monash Medical Centre
246 Clayton Road
Clayton
Victoria 3168, Australia</address>
      <phone>+61 3 95945145</phone>
      <fax />
      <email>euan.wallace@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>